Re: Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer [0.03%]
PAOLA-1研究的长期随访及卵巢癌PARP抑制剂维持治疗后的治疗格局演变
Martina Parenza Arenhardt,Angélica Nogueira-Rodrigues
Martina Parenza Arenhardt
Neoadjuvant Intralesional Targeted Immunocytokines (Daromun) in Stage III Melanoma [0.03%]
用于三期黑色素瘤的术前病灶内靶向免疫细胞因子治疗（达罗蒙）
K C Kähler,J C Hassel,M Ziemer et al.
K C Kähler et al.
Background: This phase 3 trial assessed daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant treatment for patients with clinically detectable stage IIIB/C melanoma (AJ...
Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors [0.03%]
泛RAS或KRASG12C抑制剂治疗胰腺癌的获得性抵抗基因组谱景观比较分析
Florian Castet,Tian V Tian,Teresa Macarulla
Florian Castet
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer [0.03%]
circulating肿瘤DNA早期变化对内分泌治疗敏感性乳腺癌患者预后的预测价值
A Mamann,Y Pradat,F C Bidard et al.
A Mamann et al.
Background: Patients with advanced estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer commonly develop resistance to treatment with hormone therapy and cyclin-dependent kinases 4/6 (CDK4/6) inhibitors. Re...
Updated treatment recommendation for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC Living Guideline† [0.03%]
ESMO基因成瘾性转移性非小细胞肺癌实时指南：系统治疗更新推荐意见
L E L Hendriks,F Cortiula,D Martins-Branco et al.
L E L Hendriks et al.
Navigating the Limits of Ribociclib in Early Breast Cancer: Questions from the NATALEE Trial [0.03%]
早期乳腺癌中ribociclib的局限性及其在NATALEE试验中的疑问
Qiang Hu,Xiyin Yang
Qiang Hu
Underestimating Risk? An In-Depth Examination of Prenatal Cancer Exposure Research [0.03%]
understating the risks: an in-depth examination of research on prenatal cancer exposure
Lukasz Szarpak,Michal Pruc,Andrzej Krupa
Lukasz Szarpak
Letter Re: A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial [0.03%]
关于NATALEE试验：核激素受体阳性且人类表皮生长因子受体阴性的早期乳腺癌患者在接受辅助类固醇治疗联合内分泌治疗与单独的内分泌治疗的III期临床试验的最终浸润性疾病无进展生存结果的信件报告
Xudong Zhu,Tong Zhu,Xi Gu
Xudong Zhu
Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene addicted-metastatic NSCLC Living Guideline† [0.03%]
ESMO非驱动基因依赖性晚期NSCLC指南中系统治疗部分的更新推荐†
L E L Hendriks,F Cortiula,D Martins-Branco et al.
L E L Hendriks et al.
Efficacy and Safety of Biweekly Single-Dose Actinomycin D vs Multiday Methotrexate in Low-Risk Gestational Trophoblastic Neoplasia: A Prospective Multicenter Randomized Trial [0.03%]
低危妊娠滋养细胞肿瘤单剂量阿克明丁与多日甲氨蝶呤疗效和安全性的前瞻性多中心随机试验
F Jiang,C L Guan,L Z Jiao et al.
F Jiang et al.
Background: Cure rates for low-risk gestational trophoblastic neoplasia (GTN) are high, but there is no consensus on optimal first-line chemotherapy. Here we evaluated the efficacy and safety of biweekly single-dose actin...